Oxford Nanopore Technologies Plc (Oxford Nanopore), formerly Oxford NanoLabs Ltd, develops disruptive, electronic, and single-molecule sensing systems. The company’s products include SmidgION, Flongle, MinION, PromethION and GridION used for the analysis of DNA, RNA, proteins, small molecules and other types of molecules. Its products find applications in various areas of research such as microbiology, environmental research, microbiome, basic genome research, human genetics, cancer research, clinical research, plant research, transcriptome analysis, population genomics and animal research. The company also offers support, certification and training services. It works in partnership with various academic and industry research groups to launch new genomic and medical applications through its nanopore technology. Oxford Nanopore is headquartered in Oxford, England, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Oxford Nanopore Technologies Plc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
May 28, 2024: American Association of Cancer Research: Oxford Nanopore showcases transformative technology for accelerating oncology research
May 23, 2024: Oxford Nanopore Technologies : London Calling Technology Update
Mar 11, 2024: Oxford Nanopore Technologies and SeqOne Partner to Support Interpretation of Nanopore Sequencing in Clinical Use
Mar 07, 2024: Oxford Nanopore launches PromethION 2 Integrated into open early access
Feb 29, 2024: Oxford Nanopore Technologies Announces Directorate Change
Jan 22, 2024: Oxford Nanopore Technologies Announces Expansion of Leadership Team
Nov 30, 2023: New Genomic Funding Awarded in Australia to Boost National Rare Disease Research Programme, Using Oxford Nanopore Technologies
Oct 25, 2023: Oxford Nanopore Technologies and Saphetor Announce a New Partnership to Deliver Tertiary Analysis for Comprehensive Interpretation of Nanopore Sequencing
Oct 23, 2023: Oxford Nanopore secures £70m from French diagnostics company
Oct 19, 2023: bioMérieux Makes Strategic Investment in Oxford Nanopore